Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies. To accomplish this mission, we are dedicated to achieving these goals in Washington, D.C. and across the country.

Featured Blogs

Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful

Megan Van Etten
In two years, biopharmaceutical companies have gone from zero to 13 billion COVID-19 vaccine doses produced. They’ve worked across the industry and on every continent to meet the global demand for COVID-19 innovation. Yet global trade officials will gather for the World Trade Organization (WTO) ministerial meeting in June to debate whether and how to allow countries to confiscate intellectual property (IP) rights for pandemic-related products as part of the WTO’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement.

Study after study after study: Contract pharmacy expansion not aligned in communities 340B is meant to serve

Nicole Longo
Evidence continues to show that 340B hospitals and their contract pharmacies are often not helping patients access their medicines.

Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines

Stami Williams
It’s time to put people over the bottom line. States can require PBMs, insurers and other middlemen to put patients first.